Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lung Cancer Treatment Market

Lung Cancer Treatment Market Share

Report ID: GMI5708
Published Date: May 2023
Report Format: PDF

Download Free Sample

Lung Cancer Treatment Market Share

Some of the major market players operating in the lung cancer treatment market are :

Merck KGaA
ONO PHARMACEUTICAL CO., LTD.
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc.
Pfizer Inc.
Johnson & Johnson Services, Inc.
AstraZeneca
Takeda Pharmaceutical Company Limited
Church & Dwight Co., Inc.
Sun Pharmaceutical Industries Ltd.

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for lung cancer treatment was valued at USD 15.70 billion in 2022 and will record a 12.4% CAGR between 2023 and 2032.

The targeted therapy segment had the highest revenue share of 36.6% in 2022 as it is designed to treat patients with specific genetic mutations or abnormalities.

North America lung cancer treatment market size was USD 7.17 billion in 2022 due to several factors that contribute to its growth and development, owing to the growing aging population, and technological advancements for lung cancer treatment.

Merck KGaA, GlaxoSmithKline plc., Pfizer Inc., Johnson & Johnson Services, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Church & Dwight Co., Inc., and Sun Pharmaceutical Industries Ltd.